China’s Genor Biopharma Co., Ltd (HKG: 6998) has entered into a co-development agreement with compatriot firm Abogen Biosciences Co., Ltd, a Suzhou-based mRNA drug developer. The collaboration aims to develop mRNA medicines against cancer by integrating Genor’s biologic antibody development platform with Abogen’s mRNA technology platform.
Collaboration Details
The partnership combines Genor’s first-in-class/best-in-class immuno-oncology bispecific/multi-specific antibody R&D platform with Abogen’s mRNA expertise. Genor has initiated multiple molecule discovery programs, while Abogen is known for China’s first home-grown COVID-19 mRNA vaccine, developed with the Academy of Military Sciences and Walvax Biotechnology Co., Ltd. Abogen secured clinical trial approval for the vaccine in June 2020, and it is currently in Phase III trials with a manufacturing license awarded in November last year.-Fineline Info & Tech
